Page Banner
Mayo Clinic Laboratories > Oncology > Lung cancer > Immunotherapy

Immunotherapy

Assess therapeutic response through PD-LI testing

Immunotherapies have recently emerged as a therapeutic option for patients with non-small cell lung cancer (NSCLC). Therapies have been approved for both first- and second-line treatments of NSCLC tumors with specific patterns of PD-L1 expression.

Immunotherapy test menu

Immunotherapy Immunotherapy

Immunotherapy

Mayo Clinic Laboratories offers four PD-L1 clones for assessing patient response to specific therapies. The specific PD-L1 clone, scoring method, and eligibility requirements depend on the tumor type, stage of malignancy, previous treatment outcomes, and specific PD-L1 inhibitor under consideration.

The FDA List of Cleared or Approved Companion Diagnostic Devices is frequently updated and provides current guidance for treatment indications and scoring.

Key testing

(BETA) Choose a language to view this content in:
About the translation.